Federal Register #Docket No.: PTO-P-2026-0497

USPTO Issues Interim Extension for Centanafadine Hydrochloride Patent

This notice from the United States Patent and Trademark Office (USPTO), under the Department of Commerce, announces a one-year interim extension of U.S. Patent No. 9,737,506: - The patent covers methods of using Centanafadine Hydrochloride, a drug product - The extension is granted under 35 U.S.C. 156(d)(5) due to an ongoing regulatory review period with the Food and Drug Administration (FDA) - The extension allows continued patent protection while FDA review for commercial marketing and use is pending - No procurement, contracting, or acquisition of products or services is involved - No OEMs, vendors, or suppliers are named in this notice - This is an informational notice regarding patent status, not a solicitation or award

Description

The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 9,737,506 related to Centanafadine Hydrochloride. This extension is granted under 35 U.S.C. 156(d)(5) due to an ongoing regulatory review period before the Food and Drug Administration for permission to market and use the drug product commercially. The extension is for a period of one year from the original expiration date of the patent, which is July 25, 2026. The notice informs the public of this interim patent term extension.

View original listing